TP53 and colorectal carcinoma: The requirement for LRH-1 in the growth of CRC harbouring wild-type p53 makes it a potential drug target, a possibility that undoubtedly warrants further investigation and one that should become amenable to testing with small molecule selective inhibitors of LRH-1 that are actively being sought (75–77).